Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study.
Journal Information
Full Title: Ther Clin Risk Manag
Abbreviation: Ther Clin Risk Manag
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Health Care Sciences & Services
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Disclosure The authors state that there are no potential conflicts of interest in this article."
"This work was supported by a funding from the Jiangxi Provincial Department of Science and Technology (No. 20202BAB206052)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025